NXI Therapeutics Company
NXI Therapeutics specializes in the development of innovative immunosuppressive drugs aimed at treating autoimmune diseases and facilitating organ transplantation. The company focuses on creating drugs that offer high efficacy in managing these conditions. With a team led by CEO Ruben Herrendorff, who has extensive experience in preclinical and early clinical drug research and development, particularly in autoimmune and neuromuscular diseases, NXI Therapeutics is at the forefront of addressing complex medical challenges. The company operates within the biotechnology industry and is committed to advancing the field through its research initiatives.
Founded Date:
2021-01-01
Employee Number:
1-10
Headquarters:
Basel, Basel-Stadt, Switzerland, Europe
Industry:
Drug Discovery & Development
Super Industry:
Biopharma & Life Science Tools
Phone Number:
+41 612077110
Investors:
BaseLaunch, Gebert R?f Stiftung, Kickfund, University of Basel, Venture Kick
Ipo Status:
private
City:
Basel
Region:
Basel-Stadt
Country:
Switzerland